NxStage shares dive despite new regulatory approvals and record Q1 revenues

May 5, 2011 by MassDevice staff

NxStage Medical takes a beating on Wall Street, despite reporting record first-quarter earnings and landing regulatory approvals for its System One home hemodialysis system in Australia and New Zealand.

NXTM logo

Shares of NxStage Medical Inc. (NSDQ:NXTM) dove nearly 14 percent yesterday despite record first-quarter sales growth and news of regulatory approvals on the international market.

Less than two hours after the opening bell, NXTM shares had fallen nearly 13 percent and recovered only slightly before closing at $20.43.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.